Author of

• 18974

  +

  P3.02 - Biology/Pathology (ID 620)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: Biology/Pathology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/18/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)

  • 23996

    +

    P3.02-048 - Clinicopathologic Characteristics of Non-Small Cell Lung Carcinomas Habouring MET Exon 14 Skipping Mutations (ID 9667)

    09:30 - 09:30  |  Author(s): T. Kohno
    • Abstract

    Background:
    Non–small cell lung carcinomas (NSCLC) harboring mutations involving MET exon 14 splice sites may respond to MET inhibitors. We investigated the clinicopathologic characteristics of patients with NSCLC with MET exon 14 skipping mutations.
    
    Method:
    We examined 192 patients with NSCLC with wild-type EGFR/KRAS/ALK by reverse transcritase-polymerase chain reaction combined with SYBR Green melting curve/fragment analyses to detect the presence of MET exon 14 mutation. Clinical characteristics of MET exon 14 mutated NSCLC were compared with those of NSCLC with EGFR or KRAS mutations. MET immunohistochemistry and fluorescent in situ hybridization will be performed afterwards.
    
    Result:
    MET exon 14 mutations were identified in 21 of 192 NSCLC with wild-type EGFR/KRAS/ALK (10.9%), accounting 6.6% of all NSCLC (n=319). Patients with MET exon 14–mutated NSCLC were significantly older (median age, 77 years) than patients without MET exon 14 mutation (median, 71.5 years), and 12 (57%) were men. MET exon 14-mutated NSCLC were staged as stage 0 (n=1), stage IA (n=12), stage IB (n=4), stage IIA (n=3), or stage IV (n=1). MET exon 14–mutated NSCLC were histologically adenocarcinomas (n=20), consisting of adenocarcinoma in situ (n=1), minimally invasive adenocarcinomas (n=2), invasive adenocarcinomas (n=17) including lepidic (n=7), papillary (n=7), acinar (n=5), or solid (n=1) predominant subtypes, and adenosquamous carcinoma (n=1).
    
    Conclusion:
    MET exon 14 mutations were identified in 6.6% of all NSCLC, which may represent a clinically unique molecular subtype and an important therapeutic target in NSCLC.